IL36RN and achondroplasia: Several case reports have shown that adalimumab is effective in pediatric patients with ACH, and a case involving a pediatric patient with an IL-36RN mutation exhibited a substantial improvement in their lesions after switching to adalimumab following an unsatisfactory response to secukinumab (7).